ANSM — authorised 12 November 2021
- Marketing authorisation holder: ROCHE REGISTRATION GMBH
- Status: approved
ANSM authorised IMDEVIMAB on 12 November 2021
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. ANSM authorised it on 12 November 2021.
ROCHE REGISTRATION GMBH holds the French marketing authorisation.